Mr. Michael McFadden reports

ALPHA COGNITION ANNOUNCES PRICING OF $50 MILLION UPSIZED PUBLIC OFFERING AND NASDAQ LISTING

Alpha Cognition Inc. has priced its upsized public offering of 8,695,653 common shares at a public offering price of $5.75 per share for gross proceeds of approximately $50-million, before deducting underwriting discounts, commissions and estimated offering expenses. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover overallotments at the public offering price, less the underwriting discount. All of the common shares are being offered by the company. The offering is expected to close on Nov. 13, 2024, subject to the satisfaction of customary closing conditions.

The company has received approval to list its common shares on the Nasdaq Capital Market under the symbol ACOG and is expected to begin trading on Nasdaq on Nov. 12, 2024.

The company intends to use the proceeds toward the commercialization and launch of Zunveyl in Alzheimer's disease, further research and development of its pipeline product candidates, continued commercial CMC (chemistry, manufacturing and controls) activities, and for working capital and general corporate purposes.

"This offering serves as a tremendous milestone for Alpha Cognition as we begin the commercialization of our FDA-approved [U.S. Food and Drug Administration] drug, Zunveyl, for the treatment of mild to moderate Alzheimer's disease," said Michael McFadden, chief executive officer and director of the company. "This financing puts our balance sheet in a position of meaningful strength and provides the necessary foundation for a successful commercial launch, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of Zunveyl and the exciting opportunity for our platform."

Titan Partners Group LLC, a division of American Capital Partners, is acting as sole bookrunner for the offering.

The securities were sold pursuant to a registration statement on Form S-1 (file No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Titan Partners Group, a division of American Capital Partners LLC, 4 World Trade Center, 29th floor, New York, N.Y., 10007, or by e-mail at prospectus@titanpartnersgrp.com or telephone at 929-833-1246. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained through the U.S. Securities and Exchange Commission's website.

About Alpha Cognition Inc.

Alpha Cognition is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive impairment with mild traumatic brain injury (mTBI), for which there are currently no approved treatment options.

Zunveyl is a patented drug approved as a new-generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. Zunveyl's active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and as an intranasal formulation for cognitive impairment with mTBI.

We seek Safe Harbor.